Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients
Tóm tắt
Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein, which is not only overexpressed in prostate cancers but also in variety of solid tumors including glioblastoma multiforme. The aim of the present study was to demonstrate PSMA expression in gliomas using 68Ga-PSMA-HBED-CC(PSMA 11) PET/CT.
Ten patients with initially MRI suspected and eventually histopathologically proven gliomas [8 males (age range 30–73 yr; mean age 51.8 yr); 2 females aged 39 and 55 years] were subjected preoperatively to regional brain PET scan with 68Ga-PSMA-11 and 18F-FDG PET/CT. Final histopathology of brain lesions, their MIB-1 proliferation index (MIB-1 PI) were compared with PSMA and FDG PET findings.
FDG PET/CT showed distinct FDG uptake in high-grade gliomas, whereas low-grade gliomas were non-FDG-avid amidst physiological tracer uptake. In vivo PSMA expression was seen in all patients with glioma. Of these, the 7 patients of glioblastoma harboring 8 lesions showed significantly higher PSMA expression than those with low-grade gliomas, average SUVmax being 16.93 and 2.93, respectively. Similarly, average tumor-to-background ratios (13.95 and 3.42, respectively) and MIB-1 PI (17.31 and 3.3, respectively) were substantially more in high-grade versus low-grade gliomas.
The results of this pilot study show that 68Ga-HBED-CC-PSMA PET/CT can be used to characterize the PSMA expression in gliomas, high-grade ones demonstrating higher SUVmax, MIB-1 PI tumor-to-background ratio than the low-grade ones. With these results as basis, certain patients may benefit from potential PSMA-targeted radionuclide therapy.
Từ khóa
Tài liệu tham khảo
2014, Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases, Cancer Cell Int, 14, 26, 10.1186/1475-2867-14-26
2015, Prostate-specific membrane antigen as a target for cancer imaging and therapy, Q J Nucl Med Mol Imaging, 59, 241
2015, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature, Int J Mol Sci, 16, 9573
2011, Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme, Arch Pathol Lab Med, 135, 1486, 10.5858/arpa.2010-0740-OA
2014, Management of patients with high-grade glioma, EMJ Oncol, 2, 91
2017, Diagnostic value of Ga-68 PSMA-11 PET/CT imaging of brain tumors—preliminary analysis, Clin Nucl Med, 42, e41, 10.1097/RLU.0000000000001451
2015, In vivo visualization of prostate-specific membrane antigen in glioblastoma, Eur J Nucl Med Mol Imaging, 42, 170, 10.1007/s00259-014-2921-5
2006, Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature, Microvasc Res, 72, 54, 10.1016/j.mvr.2006.03.004
2005, Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis, J Biomed Biotechnol, 2005, 287, 10.1155/JBB.2005.287
2018, Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with (89)Zr-Df-IAB2M anti-PSMA minibody, J Neurooncol, 138, 581, 10.1007/s11060-018-2825-5
2015, Applications of PET imaging of neurological tumors with radiolabeled amino acids, Q J Nucl Med Mol Imaging, 59, 70
2018, Utility of Ga-68 PSMA-11 PET/CT in imaging of glioma—a pilot study, Clin Nucl Med, 43, e304, 10.1097/RLU.0000000000002175